Results 51 to 60 of about 112,411 (265)

Effect of Systemic Immunomodulators on Incidence of Alopecia Areata: A Retrospective Cohort Study

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Alopecia areata (AA) is a chronic autoimmune hair loss disorder. Patients with primary autoimmune diseases commonly use systemic immunomodulators to manage disease and have an increased risk of developing AA. Systemic immunomodulators have diverse immunologic effects, but their impact on AA risk is not well understood. Objectives We
Angela Rose Liu, Nada Hentati, Bethany R. Rohr   +2 more
wiley   +1 more source

A Case of Pembrolizumab‐Induced Pityriasis Lichenoides‐Like Eruption Treated Successfully With Dupilumab

JEADV Clinical Practice, EarlyView.
ABSTRACT Immune‐checkpoint inhibitors (ICIs) have revolutionised melanoma treatment but can often cause severe and long‐standing cutaneous immune‐related adverse events (cirAEs). We report a case of refractory pembrolizumab‐induced pityriasis lichenoides (PL)‐like eruption successfully treated with dupilumab, leading to rapid and sustained remission ...
Evangelos Christou, Sharon Edwards, Andrew Affleck   +2 more
wiley   +1 more source

Clinical Features and Therapeutic Outcomes in Pyoderma Gangrenosum: A Prospective Cohort Study

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis highly associated with systemic comorbidities. Accurate diagnosis and treatment remain challenging due to its rarity and clinical mimickers. Objectives To evaluate demographic, clinical features and treatment outcomes in patients referred with suspected PG at a tertiary ...
David Croitoru, Nesrine Brahimi, Haleh Zabihi, Cathryn Sibbald, Kyle Seigel, Delaram Shojaei, Eric McMullen, Afsaneh Alavi, Lily Archaempong, Aaron M. Drucker, Adam Weizman, Kenneth Croitoru, Robert Inman, Vincent Piguet   +13 more
wiley   +1 more source

Professional Cleaners’ and Healthcare Workers’ Ability to Recognize Hand Eczema

Acta Dermato-Venereologica
Timely intervention reduces the risk of a poor prognosis in hand eczema, making early recognition of symptoms important in high-risk professions. However, limited data exist regarding the ability of cleaners and healthcare workers to recognize hand ...
Anna Glenn Ullum, Farnam Barati Sedeh, Gregor B.E. Jemec, Kristina Sophie Ibler   +3 more
doaj   +1 more source

Whole exome sequencing detects novel variants in Saudi children diagnosed with eczema

Journal of Infection and Public Health, 2020
Background: Eczema is also known as atopic dermatitis is well-known for the skin disease globally. In Saudi Arabia, exome sequencing studies have not been documented.
Neda M. Bogari, Amr A. Amin, Husni H. Rayes, Ahmed Abdelmotelb, Faisal A. Al-Allaf, Anas Dannoun, Hiba S. Al-Amodi, Anas A. Sedayo, Hilal Almalk, Amna Moulana, Rania Balkhair, Fatma Jambi, Fakhriah Madani, Mwafaq Abutalib, Mohiuddin M. Taher, Abdellatif Bouazzaoui, Ashwag Aljohani, Mustafa N. Bogari, Udaya Raja G.K., Ahmed Fawzy, Khalid Khalaf Alharbi, Imran Ali Khan   +21 more
doaj   +1 more source

Dyshidrotic Eczema

Enliven: Pediatrics and Neonatal Biology, 2014
Dyshidrotic eczema, also known as dyshidrotic dermatitis or pompholyx, is characterized by pruritic, tense, deep-seated vesicles mainly on the palms and lateral surfaces of the fingers. In the chronic phase, scaling, desquamation, fissuring, and, sometimes, lichenification may be seen. The peak age of onset is between 20 and 30 years of age.
Leung, Alexander K.C., Barankin, Benjamin, Hon, Kam Lun   +2 more
openaire   +2 more sources

Patient‐Reported Outcomes Selected by Paediatric Patients With Atopic Dermatitis in the Aiming High in Eczema/Atopic Dermatitis Approach

JEADV Clinical Practice, EarlyView.
We surveyed 290 paediatric patients with atopic dermatitis (AD)/their caregivers to determine troublesome AD features described as PROs. The most selected were itch (0‐ to 5‐year‐old children: 85%; children aged ≥ 6 years: 89.3%), skin appearance/condition (69.9% and 61.6%, respectively), and sleep disturbance (38.1% and 25.4%, respectively ...
Yuji Fujita, Sayuri Kajitani, Manabu Miyamoto, Yusuke Ando, Masaya Kato, Hironobu Fukuda, Yumi Yamada, Nozomu Kitahara, Norimasa Fukuda, Hideaki Shiraishi, Shigemi Yoshihara   +10 more
wiley   +1 more source

Action plans for atopic dermatitis: A survey of patient and caregiver attitudes

JAAD International, 2023
Jessica K. Johnson, MPH, Allison R. Loiselle, PhD, Lisa Butler, MBA, Wendy Smith Begolka, MBS   +3 more
doaj   +1 more source

Patients’ and Caregivers’ Experiences Navigating the Burden of Atopic Dermatitis in Argentina

Medicina
Background and Objectives: Little is known about patients’ and caregivers’ experiences with atopic dermatitis (AD) in Argentina, so a survey was administered to learn more.
Korey Capozza, Michelle Tu, Alan Schwartz, Jodi L. Johnson, Mónica Ladner   +4 more
doaj   +1 more source

Efficacy of Lebrikizumab in Patients With Severe Atopic Dermatitis Who Would be Eligible for Treatment Based on the South Korean Reimbursement Criteria

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Lebrikizumab is approved to treat patients with moderate‐to‐severe atopic dermatitis (AD). Objectives This study evaluated the 16‐week efficacy outcomes of lebrikizumab in adults and adolescents with severe AD in ADvocate trials who would be eligible for treatment based on South Korean reimbursement‐like criteria. Methods This was a
Chong Hyun Won, Chun Wook Park, Jiyoung Ahn, Joo Yeon Ko, Sang Hyun Cho, Yang Won Lee, Joo Hee Lee, Khai Jing Ng, Min Young Hong, Jinglin Zhong, Martin Dossenbach, Sang Wook Son   +11 more
wiley   +1 more source